Top Page
Argent Biopharma
(Sydney:RGT)
Argent Biopharma (RGT) vs. iShares MSCI Australia ETF (EWA)
Argent Biopharma Business Overview & Revenue Model
Argent Biopharma Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 583.45K | 891.08K | 3.39M | 4.73M |
| Gross Profit | 446.32K | 203.70K | 1.45M | 1.81M |
| EBITDA | -17.00M | -15.77M | -20.04M | -16.70M |
| Net Income | -17.84M | -17.53M | -20.82M | -16.77M |
Balance Sheet | ||||
| Total Assets | 2.47M | 10.79M | 9.88M | 23.55M |
| Cash, Cash Equivalents and Short-Term Investments | 1.02M | 702.87K | 239.82K | 1.79M |
| Total Debt | 8.29M | 1.04M | 575.14K | 4.39M |
| Total Liabilities | 11.10M | 16.61M | 18.02M | 13.66M |
| Stockholders Equity | -8.63M | -5.15M | -7.51M | 11.23M |
Cash Flow | ||||
| Free Cash Flow | -9.28M | -14.40M | -11.26M | -14.85M |
| Operating Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 |
| Investing Cash Flow | 208.83K | -140.12K | 51.75K | -2.44M |
| Financing Cash Flow | 9.39M | 14.87M | 9.31M | 9.74M |
Argent Biopharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$9.46M | -2.54 | ― | ― | ― | ― | |
41 Neutral | AU$5.98M | -1.84 | -60.84% | ― | -18.70% | 20.83% | |
40 Underperform | AU$4.56M | -0.17 | ― | ― | ― | ― | |
37 Underperform | AU$12.36M | -0.64 | -1476.79% | ― | -2.82% | 32.47% |
Argent Biopharma Corporate Events
Argent BioPharma has issued 1,000,000 fully paid ordinary shares and notified the market that these securities qualify for on‑sale without a prospectus under section 708A(5) of the Corporations Act. The company affirmed it is compliant with its financial reporting and continuous disclosure obligations and stated there is no undisclosed information that would be material to investors’ assessment of its financial position, prospects, or the rights attached to the newly issued shares, helping to maintain transparency and liquidity in its stock.
The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent Biopharma Limited, listed on the ASX under the code RGT, has applied for quotation of an additional 1,000,000 ordinary fully paid shares. The new securities, issued on 15 January 2026 following the exercise or conversion of existing options or other convertible instruments, will expand Argent Biopharma’s listed share capital, modestly increasing liquidity and potentially enabling the company to further support its funding and operational needs.
The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent Biopharma Limited has notified the ASX of its intention to issue up to 20 million new fully paid ordinary shares in a proposed placement, with an expected issue date of 16 March 2026. The additional securities, to be quoted on the ASX subject to the exchange’s agreement, represent a capital-raising move that is likely aimed at strengthening the company’s balance sheet and providing funding flexibility for its ongoing biopharmaceutical activities, with potential implications for existing shareholders through equity dilution and for the company’s capacity to advance its pipeline.
The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent BioPharma has signed a binding agreement with AusCann Group Holdings to acquire AusCann’s 48% equity stake in CannPal Animal Therapeutics for A$2 million in Argent shares, in a streamlined deal that replaces a broader prior term sheet and excludes AusCann’s EuroCann holding. The transaction, backed by Argent’s board, major shareholders and primary financier C/M Capital Partners, is designed to strengthen Argent’s clinical pipeline by providing validated preclinical and real-world data to accelerate regulatory and commercial progress for its CannEpil® cannabinoid therapy, enhance its intellectual property portfolio through an option to acquire the Neuvis® drug-delivery platform, and support early-access and named-patient programs as well as its U.S. dual-listing and partnering strategy, while also prompting board changes to align governance with the company’s next phase of growth.
The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent BioPharma has issued 5,616,000 fully paid ordinary shares, taking advantage of an exemption under section 708A(5) of the Corporations Act 2001, which allows for the on-sale of securities without disclosure. This strategic move aligns with the company’s compliance with relevant legal provisions and supports its ongoing efforts to advance its clinical programs and strengthen its market position in the biopharmaceutical industry.
Argent Biopharma Limited has announced the issuance of 5,000,000 fully paid ordinary securities to its employees under the company’s employee incentive securities plan. This move is part of their strategy to motivate and retain talent within the company. The issuance of these securities, which will be quoted on the ASX, reflects Argent Biopharma’s commitment to aligning employee interests with company performance, potentially enhancing its market position and stakeholder value.
Argent Biopharma Limited announced the issuance of 616,000 ordinary fully paid securities to its creditors, which will be quoted on the Australian Securities Exchange (ASX). This move is expected to strengthen the company’s financial position and enhance its market presence, potentially impacting its operations and stakeholder interests positively.
Argent BioPharma has announced the termination of its Chief Financial Officer, Mr. Igor Bluvstein, as part of a strategic restructuring of its finance and reporting functions. The company is transitioning its financial management activities to an external provider in Australia, a move aimed at creating a more efficient and transparent operational framework. This restructuring is intended to support Argent BioPharma’s commercial, clinical, and regulatory goals, particularly in preparation for a planned U.S. listing. The centralization of financial oversight is expected to enhance governance and reporting quality, aligning the company’s operations with its strategic objectives.
Argent Biopharma Ltd has announced the issuance of convertible notes as part of a new financing agreement with US-based institutional funds managed by C/M Capital Partners, LP. This agreement provides Argent with a substantial funding facility of up to A$11 million, with an initial tranche of A$3 million already secured. The issuance of these convertible notes is expected to increase the company’s cash reserves and potentially double its number of fully paid ordinary shares, enhancing its financial position and operational capabilities.
Argent Biopharma Limited announced the issuance of 3,300,000 convertible notes and 21,950,952 unlisted options exercisable at A$0.1025, expiring on December 3, 2028. This move is part of a previously announced transaction and reflects the company’s strategic efforts to strengthen its financial position and enhance its market operations.
Argent BioPharma announced the successful outcomes of its Annual General Meeting held on 28 November 2025, where all proposed resolutions were passed by poll. This includes key decisions such as the adoption of the remuneration report, election and re-election of directors, and ratifications of prior share issues. The approval of these resolutions supports the company’s strategic initiatives and strengthens its governance framework, potentially enhancing its market positioning and stakeholder confidence.
Argent Biopharma Ltd has announced an addendum to its Notice of Annual General Meeting, scheduled for November 28, 2025. The addendum includes new resolutions regarding the issuance and amendment of convertible notes and options, aimed at enhancing the company’s financial flexibility and investment appeal. Shareholders are advised on the procedures for voting on these additional resolutions, which could potentially impact the company’s capital structure and stakeholder interests.
Argent Biopharma Limited has announced a proposed issuance of securities, including 21,950,952 unlisted options and 11,000,000 convertible notes, set to commence on December 1, 2025. This strategic financial move is expected to bolster the company’s capital structure, potentially enhancing its market position and providing additional resources for ongoing and future projects, thereby impacting stakeholders positively.
Argent BioPharma Ltd. has secured an A$11 million financing facility from US-based C/M Capital to complete the strategic acquisition of AusCann Group assets. This acquisition will provide Argent with access to valuable drug delivery technology, a manufacturing facility in Europe, and a German distribution network, enhancing its market entry and growth in Europe. The funding also positions Argent for a dual listing on a major U.S. stock exchange, while board changes are set to align with the new company strategy. This strategic financial move is expected to strengthen Argent’s operational and financial position, supporting its growth as a globally focused biopharmaceutical company.